Efficacy of tofacitinib in an adolescent with alopecia areata and psoriasis
Vestnik dermatologii i venerologii · 2026-09-29 · 102 (4) · 93-100
DOI: 10.25208/vdv17010 ↗Abstract
Psoriasis and alopecia areata remain significant clinical challenges. These conditions severely impact patient quality of life, potentially leading to psychosocial impairment, social discomfort, and depression. The development of depression in affected adolescents is a critical concern, driven by profound psychological distress associated with altered physical appearance and diminished self-esteem. These patients frequently experience social isolation, become withdrawn, and suffer from peer bullying. This paper presents a clinical case of a 14-year-old female adolescent with a combination of two immune-mediated dermatoses: psoriasis vulgaris and alopecia totalis. The comorbidity of these conditions is of particular clinical interest, as both dermatoses share immunopathogenetic mechanisms mediated by the dysregulation of the JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway. Standard topical therapy, including topical corticosteroids, failed to yield clinically significant improvement. The initiation of tofacitinib—a selective JAK 1 and 3 inhibitor—at a dose of 5 mg twice daily resulted in marked clinical improvement at six months. This response was characterized by the cessation of hair shedding, substantial hair regrowth, clearance of psoriatic plaques, and restoration of the nail plates. This case highlights the therapeutic potential of JAK inhibitors for managing concomitant immune-mediated skin conditions in pediatric and adolescent populations.
EUVIMED